A 12-week randomized controlled trial of 15 adults with moderate kidney disease found that lanthanum carbonate, a noncalcium-based phosphate binder, reduced whole-body phosphorus balance by 451 milligrams per day compared to placebo. According to Gram Research analysis, the medication worked by blocking intestinal absorption of phosphorus and calcium, potentially helping prevent phosphorus buildup in people with normal blood phosphorus levels. However, the study was very small, and researchers have not yet confirmed whether this reduction in phosphorus balance translates to real health benefits like reduced heart disease risk.
Researchers tested a medication called lanthanum carbonate on people with moderate kidney disease who had normal phosphorus levels. In a small 12-week study, the drug helped reduce the amount of phosphorus and calcium their bodies absorbed from food compared to a placebo. This is important because high phosphorus levels can damage the heart in people with kidney disease. However, the study was very small, so scientists need to do more research to confirm whether this benefit actually prevents heart problems in real patients.
Key Statistics
A 2026 randomized controlled trial of 15 adults with stage 3b-4 chronic kidney disease found that 12 weeks of lanthanum carbonate treatment reduced whole-body phosphorus balance by 451 milligrams per day compared to placebo, from positive 320 mg/day to negative 131 mg/day.
In the same 2026 trial, lanthanum carbonate reduced calcium balance by 456 milligrams per day compared to placebo, from positive 410 mg/day to negative 46 mg/day, indicating reduced intestinal absorption of both minerals.
The 2026 study of lanthanum carbonate in 15 kidney disease patients showed the medication increased fecal phosphorus excretion without significantly changing urine phosphorus output, demonstrating that the drug works primarily by blocking intestinal absorption rather than affecting kidney function.
The Quick Take
- What they studied: Whether a phosphorus-blocking medication called lanthanum carbonate could reduce how much phosphorus and calcium the body absorbs in people with moderate kidney disease who had normal phosphorus levels.
- Who participated: 15 adults with stage 3b-4 chronic kidney disease (moderate kidney damage) with an average age of 65 years. All had normal blood phosphorus levels at the start.
- Key finding: After 12 weeks, people taking lanthanum carbonate had much lower phosphorus balance (negative 131 mg per day versus positive 320 mg per day with placebo) and lower calcium balance (negative 46 mg per day versus positive 410 mg per day with placebo).
- What it means for you: This medication may help prevent phosphorus buildup in people with kidney disease, which could reduce heart damage risk. However, this was a very small study, so talk to your doctor before considering this treatment. More research is needed to confirm real health benefits.
The Research Details
This was a randomized controlled trial, which is one of the strongest types of medical studies. Researchers randomly assigned 15 people with moderate kidney disease to receive either lanthanum carbonate (a medication that blocks phosphorus absorption) or a placebo (fake pill) for 12 weeks. Neither the participants nor the researchers knew who was getting the real drug, making it double-blind.
After the 12-week treatment period, all participants ate a controlled diet with exactly 1,000 milligrams of phosphorus and 800 milligrams of calcium per day for 9 days. They then stayed overnight in a research center where scientists carefully measured everything they ate, drank, and excreted. Researchers collected all urine and stool samples over 48 hours to calculate phosphorus and calcium balance, which shows whether the body was absorbing more or less of these minerals than it was eliminating.
Phosphorus balance is calculated by measuring how much phosphorus enters the body through food minus how much leaves through urine and stool. A negative balance means the body is losing more phosphorus than it absorbs, while a positive balance means it is storing phosphorus.
This research approach is important because it directly measures what happens to phosphorus and calcium in the body, rather than just looking at blood levels. In kidney disease, blood phosphorus can appear normal even when the body is storing too much phosphorus overall. By measuring actual balance, scientists can detect problems earlier and understand whether medications are truly working at the whole-body level.
This study has both strengths and weaknesses. Strengths include the randomized, double-blind design, which reduces bias, and the precise measurement of phosphorus and calcium balance using controlled diet and complete collection of body waste. The main weakness is the very small sample size of only 15 people, which limits how much we can trust the results. The study also only lasted 12 weeks, so we do not know if the effects continue longer. Additionally, all participants had normal phosphorus levels, so results may not apply to people with high phosphorus.
What the Results Show
The main finding was that lanthanum carbonate significantly reduced whole-body phosphorus balance compared to placebo. People taking the medication had a phosphorus balance of negative 131 milligrams per day, meaning their bodies were losing phosphorus. In contrast, the placebo group had a positive balance of 320 milligrams per day, meaning their bodies were storing phosphorus. This difference was statistically significant, meaning it was unlikely to be due to chance.
Calcium balance also differed between groups. The lanthanum carbonate group had a negative calcium balance of negative 46 milligrams per day, while the placebo group had a positive balance of 410 milligrams per day. This was also statistically significant. The medication appeared to work by reducing how much phosphorus and calcium the intestines absorbed from food, as shown by higher amounts of these minerals in stool samples from the lanthanum carbonate group.
Interestingly, the amount of phosphorus and calcium excreted in urine was similar between groups. The 24-hour urine phosphorus was 388 milligrams per day in the lanthanum carbonate group versus 513 milligrams per day in the placebo group, but this difference was not statistically significant. This suggests the medication primarily affects intestinal absorption rather than kidney function.
The study measured fecal calcium and phosphorus excretion, which showed that people taking lanthanum carbonate excreted more of both minerals in their stool. This confirms that the medication works by blocking absorption in the intestines rather than affecting the kidneys. The net absorption results also supported this finding, showing lower intestinal absorption of both minerals in the lanthanum carbonate group.
According to Gram Research analysis, very little was previously known about phosphorus balance in people with moderate kidney disease who have normal blood phosphorus levels. Most research has focused on people with advanced kidney disease or high blood phosphorus. This study fills a gap by showing that even in people with normal blood phosphorus, the body may be storing too much phosphorus. The finding that a noncalcium-based phosphate binder can reduce phosphorus balance is new, as previous studies focused mainly on calcium-based binders or looked at blood levels rather than whole-body balance.
The most important limitation is the very small sample size of only 15 people, which makes the results less reliable and harder to apply to larger populations. The study only lasted 12 weeks, so we do not know if the effects continue over months or years. All participants had normal blood phosphorus levels, so the results may not apply to people with high phosphorus. The study did not measure whether reducing phosphorus balance actually improves health outcomes like heart disease prevention. Additionally, the controlled diet and inpatient stay are not realistic for everyday life, so results may differ in real-world conditions.
The Bottom Line
Based on this small study, lanthanum carbonate may help reduce phosphorus buildup in people with moderate kidney disease and normal blood phosphorus levels. However, confidence in this recommendation is low due to the small sample size. This medication should only be considered under close medical supervision and after discussing risks and benefits with a kidney specialist. More research is needed before this becomes standard treatment.
This research is most relevant to people with stage 3b-4 chronic kidney disease (moderate kidney damage) who have normal blood phosphorus levels. It may also interest kidney doctors looking for ways to prevent phosphorus buildup before it becomes a problem. People with advanced kidney disease or those already on dialysis should not assume these results apply to them. People with normal kidney function do not need to worry about this medication.
In this study, the medication reduced phosphorus balance within 12 weeks. However, it is unclear how long it takes to see real health benefits like reduced heart disease risk. Kidney disease develops slowly over years, so any benefits from reducing phosphorus balance would likely take months or years to become noticeable in terms of heart health or bone health.
Frequently Asked Questions
What is lanthanum carbonate and how does it work in kidney disease?
Lanthanum carbonate is a medication that binds to phosphorus in the intestines, preventing the body from absorbing it. In a 2026 trial of 15 kidney disease patients, it reduced phosphorus balance by 451 mg/day compared to placebo. The drug is designed to help prevent phosphorus buildup, which can damage the heart in people with kidney disease.
Do I need phosphorus-lowering medication if my blood phosphorus is normal?
This is unclear and requires discussion with your kidney doctor. A 2026 study suggests that even with normal blood phosphorus, the body may be storing excess phosphorus. However, this was a very small study, and we do not yet know if reducing phosphorus balance in people with normal levels actually prevents heart disease or improves health outcomes.
How long does it take to see benefits from lanthanum carbonate?
This study showed effects within 12 weeks, but that is the shortest timeframe measured. Real health benefits like reduced heart disease risk would likely take much longer to appear, possibly months or years. Your doctor can monitor your phosphorus balance and kidney function with regular blood tests to assess whether the medication is working for you.
Is lanthanum carbonate better than calcium-based phosphorus binders?
This study compared lanthanum carbonate to placebo, not to calcium-based binders. The advantage of noncalcium-based binders is that they do not add extra calcium to the body, which can cause problems in kidney disease. Talk to your kidney specialist about which type of binder is best for your individual situation.
What are the side effects of lanthanum carbonate?
This study did not focus on side effects, but common ones include constipation, nausea, and stomach upset. Some people experience bone or muscle pain. Report any side effects to your doctor, as they may need to adjust your dose or try a different medication. Do not stop taking it without medical guidance.
Want to Apply This Research?
- If prescribed lanthanum carbonate, track daily phosphorus intake from food using a nutrition app, aiming for the recommended amount for your kidney stage. Log medication adherence daily and note any side effects like constipation or nausea.
- Work with a kidney dietitian to identify high-phosphorus foods to limit, such as processed meats, dairy products, nuts, and cola drinks. Use the app to log meals and phosphorus content, gradually reducing intake to recommended levels while taking the medication as prescribed.
- Schedule regular blood tests to monitor phosphorus, calcium, and kidney function every 3 to 6 months. Track any changes in energy, bone pain, or heart symptoms. Keep a log of medication side effects and discuss results with your nephrologist at each visit to assess whether the medication is working for your individual situation.
This research describes a small clinical trial and should not be used to make medical decisions without consulting a healthcare provider. Lanthanum carbonate is a prescription medication that requires medical supervision. If you have chronic kidney disease, talk to your nephrologist (kidney specialist) before starting any new medication, including phosphate binders. The findings from this 15-person study need confirmation in larger trials before becoming standard treatment. Individual results may vary based on your specific kidney function, diet, and other medications. This article is for educational purposes only and does not replace professional medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.